David Simpson
CEO Iksuda Therapeutics
Dave founded IKSUDA Therapeutics in 2012 and has >25 years of experience in Biotech & Pharma, primarily in the development & commercialization of biotherapeutics.
IKSUDA, now a clinical stage ADC company is focussed on the development of FIC/BIC class ADCs by deploying enabling chemistry platforms and Known/Novel payloads to address the challenges of haematological and solid cancers.
Previously, Dave established Eden Biodesign – a CDMO service to biotech clients across the world. Acquired by Watson Pharmaceuticals in 2010, Dave led several Biosimilar programs through clinical/commercial development.
Seminars
Discover what drives licensing decisions, investment strategies, and M&A activity, from making your ADC programmes attractive to where the next shift in the industry is heading. As large pharma companies increasingly compete for differentiated ADC platforms and clinical-stage assets, understanding the data, innovation, and risk factors behind successful deals has never been more important.
- Discussion 1 – Building the Next Wave of ADC Drugs Through Biopharma Acquisitions & Technology Scouting
- Discussion 2 – Turbocharging Biotech Innovation & Differentiation to Achieve Successful Fund Raising Rounds
- Outlining the latest trends across the ADC landscape in 2027 and future vision to develop and deliver novel ADCs with meaningful patient impact with safety and efficacy
- Highlighting methods to best pursue ADC clinical differentiation across patient selection technologies, combination strategies, and well-executed clinical design
- With clinical trials advancing in the Far East and Australia, what opportunities does this open for the ADC industry to progress faster?
